These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10840412)

  • 21. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Unresolved questions in hormonal therapy for prostate cancer].
    Oishi K
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1928-33. PubMed ID: 8085843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
    Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
    [No Abstract]   [Full Text] [Related]  

  • 26. Intermittent androgen blockade or continuous androgen blockade in advanced prostate cancer: a meta-analysis of efficacy, quality of life and side effects.
    Zhu J; Wang Y; Xu S; Sun Z
    J BUON; 2012; 17(2):350-6. PubMed ID: 22740217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
    Halabi S; Vogelzang NJ; Ou SS; Small EJ
    J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High risk biochemical relapse and the timing of androgen deprivation therapy.
    Ryan CJ; Small EJ
    J Urol; 2006 Dec; 176(6 Pt 2):S61-5. PubMed ID: 17084171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight.
    Tunn U
    BJU Int; 2007 Jan; 99 Suppl 1():19-22; discussion 23-4. PubMed ID: 17229164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M; Goldenberg SL; Bhagirath K; Gleave M
    Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should intermittent androgen deprivation be used in routine clinical practice?
    Bhandari MS; Crook J; Hussain M
    J Clin Oncol; 2005 Nov; 23(32):8212-8. PubMed ID: 16278475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.